- JAB-3312, Jacobio’s Second Innovative Drug, has Obtained FDA’s Approval for Clinical Study 2019-07-09
- Jacobio's Innovative Drug Approved for Phase IIa Clinical Study in Multiple Solid Tumors and Awarded Orphan Drug Designation for the Treatment of Esophageal Cancer by US FDA 2019-06-19
- Jacobiopharma won the Zhongguancun high tech Enterprises 2017-05-05
- Jacobio post doctoral research workstation was set up 2018-01-15
- JAB-3068 Clinical Program Discussion Meeting Successfully Held 2017-12-05
Jacobio Pharmaceuticals Co. Ltd., founded in 2015, is committed to the health development of human beings and the development of original new drugs with independent intellectual property rights in the world.
Senior Management Team
Innovative medicine leader
Our vision is to be a leader in innovative drugs, a promoter for new drug developers, and to provide more products and solutions for the health development of humans.